On June 22, Axinn partners David Silverstein and Stacie Ropka participated in ACI’s 12th Annual Summit on Biosimilars & Innovator Biologics virtual conference. David moderated a panel entitled, "Skinny Labeling Post-GSK v. Teva: How the Decision Will Inform Biosimilar Carve-Outs." Stacie spoke on a panel entitled, "Advocating for Diversity in IP: Practical Ideas for Implementing Change."
David's panel outlined the implications of the Federal Circuit decision striking down labeling carve-outs. Stacie’s panel identified best practices for evaluating your outside firm’s efforts in promoting diversity.
Click here for more information.